Aprea Therapeutics (APRE) reported second-quarter 2026 financial results and provided updates on its oncology pipeline, including the ongoing Phase 1 ACESOT-1051 trial of oral WEE1 inhibitor APR-1051.
The company reported a net loss of $3.6 million, or $0.07 per basic and diluted share, for the quarter ended June 30, 2026. Cash and cash equivalents totaled $41.2 million at quarter-end, which Aprea said is expected to fund currently projected operating expenses and capital expenditures into the first quarter of 2028.
- Grant revenue was $0 for the second quarter of 2026, compared with $118,111 a year earlier.
- Operating loss was $4.0 million, compared with $3.4 million in the second quarter of 2025.
- Research and development expenses were $2.5 million, up from $1.9 million in the prior-year quarter.
- General and administrative expenses were $1.6 million, unchanged from the year-earlier quarter.
- Aprea expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.
- The company plans to expand APR-1051 development in uterine serous carcinoma, Cyclin E-overexpressing platinum-resistant ovarian cancer, and combination regimens in HPV-positive head and neck cancer and colorectal cancer.
$APRE Hedge Fund Activity
We have seen 8 institutional investors add shares of $APRE stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 350,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $267,015
- MURCHINSON LTD. removed 340,139 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $259,492
- DRW SECURITIES, LLC removed 120,651 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $92,044
- GEODE CAPITAL MANAGEMENT, LLC added 78,181 shares (+190.9%) to their portfolio in Q1 2026, for an estimated $59,644
- SCIENTECH RESEARCH LLC added 60,281 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,988
- MORGAN STANLEY removed 54,700 shares (-71.0%) from their portfolio in Q1 2026, for an estimated $41,730
- CITADEL ADVISORS LLC removed 51,041 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $38,939
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
